The James Lind Alliance Tackling treatment uncertainties together Lester Firkins, John Scadding and Mark Fenton INVOLVE Conference 2006.

Slides:



Advertisements
Similar presentations
Nina Dunham R&D Manager
Advertisements

Case studies: Identifying the treatment uncertainties of people with asthma & their clinicians Colin Gelder Asthma Editor DUETs.
Generating evidence to inform, difficult decisions: building capacity through investment and partnership Chris Henshall Pro Vice Chancellor for External.
Introduction to the unit and mixed methods approaches to research Kerry Hood.
Towards a New R&D Strategy A blueprint for R&D in Health and Social Care Noreen Caine Deputy Director of R&D, DH NHS R&D Forum Annual Conference May 2005.
Driving improved quality in respiratory care - levers and tools from national policy Bronwen Thompson, Policy adviser to PCRS-UKJune 2013.
Definitions Patient Experience Patient experience at NUH results from a range of activities that all impact upon patient care, access, safety and outcomes.
1. Choosing outcomes and measures - for doing and using research James Lind Alliance Outcomes in clinical research – whose responsibility? 20 November.
We need user-led research more now than ever before…
Introduction to the User’s Guide for Developing a Protocol for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research.
Danish Nursing Society Improving Nursing by Clinical Guidelines and Documentation. How to organize the work?
The James Lind Alliance ….. the story so far. NICE Conference Tackling Health Priorities 7 th December 2006.
Avoiding waste in research: the role of public involvement Iain Chalmers Coordinator, James Lind Initiative ‘Putting people first in research’ INVOLVE.
Subject Selection and Recruitment David Wendler Department of Clinical Bioethics NIH, USA.
Clinical trials methodology group Simon Gates 9 February 2006.
National COPD Programme Building QI into Your Audit from the Start Prof. Mike Roberts Royal College of Physicians Barts Health/ UCLPartners On behalf of.
Introduction to evidence based medicine
Assessing information provided by national funding agencies using the “reducing waste of research” framework Mona Nasser - Clinical Lecturer in Evidence.
Why Return on Investment (ROI) Matters Raimo Vuorinen presenting for: James P. Sampson, Jr. Florida State University.
Copyright 2011 Right Care The Accountable Integrated Care System Sept 2011 Commissioning for Value.
Creating a service Idea. Creating a service Networking / consultation Identify the need Find funding Create a project plan Business Plan.
999 EMS Research Forum Prioritisation of topics for research in prehospital care
Embedding Research in Practice Judy Lawrence RD PhD
Evaluation Trials and Studies Coordinating Centre 5 July 2013 NIHR Programmes and topic identification Alison Ford, Senior Programme Manager.
An introduction to the JLA. What will I cover? What is the James Lind Alliance (JLA)? What do we do? How do we do it? What difference does it make?
Module 3. Session DCST Clinical governance
Stephen Cole SICSAG September 2009 “making donation usual, not unusual”
Medical Audit.
An introduction to the JLA Katherine Cowan. What will I cover? What is the James Lind Alliance (JLA)? What do we do? How do we do it? What difference.
The Audit Process Tahera Chaudry March Clinical audit A quality improvement process that seeks to improve patient care and outcomes through systematic.
James Lind Alliance Working Partnership on Urinary Incontinence.
Systematic Reviews.
Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.
EBM for the busy Clinician Gil C. Grimes, MD EBM Working Group, Department Family Medicine Scott & White.
SSRG Annual Workshop 2008 SCIE’s role in making a difference Julie Jones Chief Executive, SCIE 9 April 2008.
Balancing the importance of getting some information vs. the importance of getting good quality information Dr Simon Day.
Liberating the NHS - A consultation on proposals Transparency in outcomes: a framework for the NHS.
Evaluation, Trials and Studies Coordinating Centre Developing Sight Loss and Vision research questions: a funder’s perspective Anna Tallant Scientific.
James Lind Alliance Tackling treatment uncertainties together James Lind,
James Lind Initiative Database of Uncertainties about the Effects of Treatments (DUETs) what gaps in the evidence matter to patients and doctors? Iain.
“What’s in it for us?” NICE Guideline: Safe and Effective use of Medicines (Medicines Optimisation) Erin Whittingham Public Involvement Adviser Public.
Is the conscientious explicit and judicious use of current best evidence in making decision about the care of the individual patient (Dr. David Sackett)
How can research be better informed by the direct involvement of the autistic community and broader autism community? Richard Mills July
Open to all: the role of public involvement in health research Faculty of Health and Social Care, Open University, Wednesday 9 th December 2015 Simon Denegri,
1 National Forum on Biomedical Imaging in Oncology CMS UPDATE Steve Phurrough MD, MPA Director, Coverage and Analysis Group.
Pilot and Feasibility Studies NIHR Research Design Service Sam Norton, Liz Steed, Lauren Bell.
NIHR Themed Call Prevention and treatment of obesity Writing a good application and the role of the RDS 19 th January 2016.
European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.
Patient and public involvement (PPI) in setting the research agenda Dr Noémi Roy Oxford Molecular Haematology.
HTA Efficient Study Designs Peter Davidson Head of HTA at NETSCC.
Why are systematic reviews important? Iain Chalmers Editor, James Lind Library Cochrane Workshop Independent University, Bangladesh.
An Imperfect Model for Democratic Decision Making Gemma Stacey, Philip Houghton & James Shutt Representing Critical Values Based Practice Network
Advocacy and the role of the Healthcare Support Worker “ Advocacy is concerned with promoting and protecting the interest of people in the care of nurses.
Customised training: Controversial issues and post-16 citizenship.
R&D Report to SL&M Board 17 September 2002 Graham Thornicroft Director of Research & Development Gill Dale Research & Development Manager.
NIHR Southampton Biomedical Research Centre The Southampton Biomedical Research Centre is funded by the National Institute for Health Research (NIHR) and.
Medicines adherence Implementing NICE guidance 2009 NICE clinical guideline 76.
Evidence-Based Mental Health PSYC 377. Structure of the Presentation 1. Describe EBP issues 2. Categorize EBP issues 3. Assess the quality of ‘evidence’
Safety in Medicines: Raising the profile with the Royal Pharmaceutical Society Liz Rawlins Communications Officer 9 May 2011.
Cochrane Agenda and Priority Setting Methods Group (CAPSMG)
Ghada Aboheimed, Msc. Review the principles of an evidence based approach to clinical practice. Appreciate the value of EBM Describe the 5 steps of evidence.
Critical Care Services Pharmacist Royal Manchester Children’s Hospital
Evidence-based Medicine
Designing Research that Improves Health and Wellbeing for All How the NIHR Research Design Service North East can help.
@hrbtmrn Intro and welcome.
Pragmatic RCTs and the Learning Healthcare System
Jason Gerson, PhD Clinical Effectiveness and Decision Science
Ten Key Trials in Cardiovascular Surgery
Study within a Trial (SWAT) to increase the evidence for trial recruitment and retention in decision making -Shaun Treweek From the UK Trial Managers.
Supporting Priority Setting Partnerships
Presentation transcript:

The James Lind Alliance Tackling treatment uncertainties together Lester Firkins, John Scadding and Mark Fenton INVOLVE Conference 2006

James Lind Alliance WHO?……Are they WHAT?…..Do they do HOW?…….Do they do it WHEN?…..Will they do it WHY?…….BOTHER

WHO? Convened in 2004 by: –James Lind Library –INVOLVE –Royal Society of Medicine Secretariat funded by DH and MRC ( 6 part-time do’ers; an excellent overview committee and 100+ Affiliates)

WHAT? To increase the focus of the therapeutic research agenda on questions and priorities shared by patients and clinicians. To promote working partnerships and collaborations between patients and clinicians to identify and promote their shared priorities for therapeutic research. To increase general awareness and understanding of the need to refocus the therapeutic research agenda.

WHY….. BOTHER? What influences Research at the moment? Over to you……. Let us know what you think currently influences priorities in research

HOW? Address the questions of uncertainties, in any given area, by assembling the unanswered questions from a variety of sources. Work with and support “Working Partnerships” of patient groups and clinician groups to identify to prioritize these unanswered questions about the effects of treatments

ADVANTAGES of WORKING PARTNERSHIPS Address issues of importance & relevance to patients: recognise mismatches in therapeutic research. Patients & clinicians set priorities for research, not industry. Working together minimises biases of individuals. Involvement of patients in setting research agenda: better recruitment to trials and understanding of trial methods (RCT). Identification of under-researched but important treatments.

ADVANTAGES of WORKING PARTNERSHIPS Identification of systematic reviews needed. Potentially, easier passage of research proposals through ethics committees. Prospect of attraction of non-commercial funding. Ensure the most relevant trials are conducted: new vs best existing treatment. Ensure trials of existing treatments for “indication switches”. Greater involvement of NHS clinicians in therapeutic research. More research done as part of routine NHS healthcare.

HOW? WPs: patients ( and/or advocates) and clinicians. Organisations representing patients and clinicians: advantages:representative, potentially better balance. authoritative, higher external profile. disadvantages:difficulty establishing agreed views within large organisations. lack of clearly defined responsibility. repeated referral back to organisation for approval. Success of non-organisation based methods, eg RA.

CHALLENGES Ability to work together; skills needed to reach consensus decisions. Ensure clinicians and patients in WPs are representative of the condition. Set aside personal (and institutional) agendas. Clinicians must accept need to work to patient defined outcomes and preferred interventions to be investigated. Work must be done within NHS framework: research becomes a part of routine care, with need to engage HNS managers and funders. Obtaining funding for trials prioritised by WPs.

Identifying patients’ and clinicians’ questions about the effects of treatments Mark Fenton Database of Uncertainties about the Effects of Treatments (DUETs) and Secretariat, James Lind Initiative

Address the questions of uncertainties, in any given area, by assembling the unanswered questions from a variety of sources. HOW?

Challenges Identifying outcomes that matter to patients Harvesting patients’ and clinicians’ unanswered questions about the effects of treatments

Identifying outcomes that matter to patients Everything works! If you use outcomes that a patient or clinician wouldn’t recognise What do you want treatments to do? what should researchers measure how should they decide on the question to answer?

Do automated/mechanical chest compression devices improve survival in adult out-of-hospital cardiac arrest? –Outcome – Mortality – No difference –Outcome – Survival – a non statistically significant increase of 40% in the "risk" of surviving Identifying outcomes that matter to patients

Alexander J, Tharyan P, Adams C, John T, Mol C, Philip J. British Journal of Psychiatry Jul;185:63-9 Rapid tranquillisation of violent or agitated patients in a psychiatric emergency setting. Pragmatic randomised trial of intramuscular lorazepam v. haloperidol plus promethazine.

‘.. carers said they wanted to see their relatives quiet and not causing a problem in minutes. They were for the use of injections, if needed ( people respect injections, sometimes inappropriately, in these parts). Most were not for the use of restraints, unless absolutely necessary. The patients themselves were grateful that they were given treatments that got them better but their opinions were more mixed than the carers.’ Identifying outcomes that matter to patients

DUETs’ working definition of uncertainty about the effects of treatments No up-to-date systematic reviews exist OR Up-to-date systematic reviews show that uncertainty exists

Harvesting questions for DUETs Sources of uncertainties about the effects of treatments Patients and carers Patient information/advice services (e.g. Asthma UK, NHS Direct, interviews) Clinicians Clinical question answering services (e.g. NLH's Primary Care Question Answering Service) Other sources (e.g. BMJ Clinical Evidence) Systematic reviews, clinical guidelines, policy makers Registers of ongoing research

To visit DUETs go to:

Long Term Goals Better quality and relevant research Informal Network of Working Partnerships who support each other Funding is attracted to those propositions that carry a Consumer / Clinician badge It becomes “the way we do things round here”

W.I.F.M. The JLA is just one vehicle where real people with personal experiences can add value, by working with clinician groups. It may seem more hard work to involve “the public” but the JLA is convinced that it is the preferable way And for you … –Confidence that you are spending time on the right things to change peoples’ lives –Ability to put faces to conditions - it’s always personal –Huge support and encouragement –Easier route through governance –Funding

Over to you … James Lind Alliance – Summertown Pavillion Middle Way, Oxford OX2 7LG